Connect your AI

Cardinal Health CAH Pharmaceutical and Specialty Solutions — Goodwill, Impairment Loss

Other segment segments

Cost of product sold

$90M-73.3%

Other Segments

$0—

Similar metrics at other companies

CLMTSpecialty Products And Solutions — Goodwill Impairment

$0—

OPKPharmaceutical — Goodwill Impaired Accumulated Impairment Loss

$11.7M—

CSWSpecialized Reliability Solutions — Goodwill, Impairment Loss

$0—

RPMSpecialty Products Group — Goodwill Impairment

$2.85M—

JNJPharmaceutical — Goodwill (Note 3)

$14.81B+35.8%

FLOCProduction Solutions — Goodwill Impairment

$0—

Other financials

Income statement

Revenue$60.9B+11.0%

Gross profit$2.5B+17.7%

Operating income$509.0M-30.3%

Net income$399.0M-21.1%

EPS (diluted)$1.69-19.5%

Balance sheet

Cash & equivalents$3.9B+18.4%

Total debt$8.9B+16.1%

Total equity-$2.8B+3.9%

Total assets$56.7B+13.7%

Cash flow

Operating cash flow$1.8B-37.6%

CapEx$146.0M+15.9%

Free cash flow$1.7B-40.0%

Valuation

Market cap$54.98B+41.0%

Enterprise value$59.96B+38.3%

P/E35.4×+10.3×

P/S0.2×0.0×

Profitability

Gross margin3.8%+0.2pp

Operating margin0.9%-0.1pp

Net margin0.6%-0.1pp

FCF margin1.7%+0.6pp

Returns & leverage

Return on equity37.4%—

Debt / equity4.1×—

Current ratio0.9×0.0×

Where this comes from

Reported directly by Cardinal Health in its filing.

Tagged under the XBRL concept us-gaap:GoodwillImpairmentLoss.

The official record: Cardinal Health’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cardinal Health's pharmaceutical and specialty solutions — goodwill, impairment loss.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Cardinal Health's pharmaceutical and specialty solutions — goodwill, impairment loss?: Cardinal Health (CAH) reported pharmaceutical and specialty solutions — goodwill, impairment loss of $184M in Q1 2026.
What does pharmaceutical and specialty solutions — goodwill, impairment loss mean?: The charge recognized when the carrying amount of goodwill in the Pharmaceutical and Specialty Solutions segment exceeds its implied fair value. This reflects a downward revision in the expected future economic benefits of previously acquired businesses. It serves as a critical indicator of underperformance or adverse market changes affecting the segment.